March 9th, 2013
ACC.13 Headquarters
CardioExchange Editors, Staff
CardioExchange is dedicated to bringing you the latest from ACC.13. Check out our coverage below ─ and some of the great debates these posts have sparked ─ then tell us what you think!
News:
- Following an Embargo Break PREVAIL Trial Won’t be Presented at ACC
- HPS2-THRIVE: A ‘Disappointing But Clear’ Result
- Cangrelor During PCI May Reduce Ischemic Events
- Fibrinolysis May Benefit Late-Arriving STEMI Patients
- Eplerenone May Prevent Heart Failure in Acute STEMI Patients
- Another Negative Trial of Darbepoetin Alfa
- Was Atherosclerosis the Real Curse of the Mummy?
- Two Trials Explore On-Pump Versus Off-Pump Bypass Surgery
Analysis:
Follow our Fellows:
- The Real World Intrudes on the Start of the Meeting
- A Fellow Reflects on the Program and on her Progress from Observer to Educator
- Data Sources for Young Investigators
- New Approaches to LDL Lowering
- Great Venue, Great Sessions, but Disappointments Too
- Thinking About What Comes After Fellowship
- The Real Question About Reducing Hospital Readmissions
- You Are My Sunshine
- Learning to Network
NEJM — Recent Cardiology Articles- The COBRRA Trial — Ending the Venous Thromboembolism Safety Toss-up March 12, 2026The landscape of treatment options for venous thromboembolism was transformed by the arrival of direct oral anticoagulants. Large-scale trials showed that the direct oral anticoagulants apixaban and rivaroxaban were noninferior to vitamin K antagonists in terms of efficacy and had a better safety profile. However, for over a decade, a...
- Case 8-2026: A 57-Year-Old Woman with Chest Pain, Dyspnea, and Syncope March 12, 2026A 57-year-old woman was evaluated because of 2 days of chest pain and dyspnea. Ultrasonography showed a pericardial effusion with diastolic inversion of the right ventricle. A diagnosis was made.
- Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism March 12, 2026In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
- Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome March 5, 2026A CD19-targeted therapy induced remission in a woman with refractory immune thrombocytopenia and antiphospholipid syndrome by stabilizing platelet counts, eliminating pathogenic antibodies, and enabling safer long-term anticoagulation.
- Assessing Nonculprit Coronary-Artery Lesions in STEMI March 5, 2026Multivessel coronary artery disease is seen on invasive coronary angiography in approximately 50% of patients presenting with acute ST-segment elevation myocardial infarction (STEMI). Previous trials have shown that in patients with hemodynamically stable disease, revascularization with percutaneous coronary intervention (PCI) of a nonculprit coronary lesion results in better outcomes than...
- The COBRRA Trial — Ending the Venous Thromboembolism Safety Toss-up March 12, 2026